GSE209887
LSD1 inhibition disrupts super-enhancer activities in CRPC [RNA-seq]
Our studies revealed a novel oncogenic function of LSD1 in driving PCa progression by activating MYC signaling and mediating CRPC SEs activities, cotargeting LSD1 and BRD4 achieved significant synergistic effects in repressing CRPC tumor growth Overall design: CRPC xenograft models were treated with LSD1 inhibitor and BET inhibitor alone or in combination (LSD1 inhibitor with lower dosage). All RNA-seq samples contain replications.